+44 115 7870500
DevelRx Logo
HomeTeam
Services
Research & Candidate SelectionDrug DevelopmentRegistrationMarketing
News & EventsPartnersContact

Professor David Heal, Dr Sharon Smith and Dr Reem Elbekai will be co-presenting two posters on Centanafadine at the American College of Toxicology (ACT) Virtual Meeting (November 12th to 19th 2020).

Back to News & Events

Professor David Heal, Dr Sharon Smith and Dr Reem Elbekai will be co-presenting two posters on Centanafadine at the American College of Toxicology (ACT) Virtual Meeting (November 12th to 19th 2020).

Centafadine is Otsuka’s drug-candidate that is in late-stage development for the treatment of ADHD and the posters report experimental results from the non-clinical assessment of Centanafadine’s risk for human abuse.

The poster session is scheduled for Monday 16th November at 17.00 – 18.30h (EST) [22.00-23.30h (UK time)].

P: 507

An investigation of the reinforcing potential of centanafadine in rats trained to self-administer cocaine.

David Heal, Sharon Smith, Harriet Day, Zara Turnbull, Reem Elbekai

P: 518

An investigation of the discriminative properties of centanafadine in rats trained to discriminate d-amphetamine from saline.

Reem Elbekai, Helen Rowley, David Heal

DevelRx Logo

Biocity,

Pennyfoot Street,

Nottingham,

Nottinghamshire,

NG1 1GF

Legal

Cookie PolicyPrivacy PolicyTerms & Conditions
inform@develrx.com

Registered in England and Wales

Company number: 12028847